drugset
drugset / Trial / NCT02817516

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants

NCT02817516 ↗

Phase 1 Terminated 24 enrolled Takeda
RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of TAK-828 in healthy participants.

Timeline

Start
2016-06-30
Primary completion
2016-08-22
Completion
2016-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-828 Unknown 15 mg Oral
Subject TAK-828 Unknown 45 mg Oral
Subject TAK-828 Unknown 75 mg Oral
Subject TAK-828 Unknown 100 mg Oral

Indications

No indication recorded.